Kevin Charles  Gorman net worth and biography

Kevin Gorman Biography and Net Worth

Kevin C. Gorman, Ph.D., is a founder and has been employed with the Company since 1993. Dr. Gorman was appointed President and Chief Executive Officer in January 2008 after serving as Executive Vice President and Chief Operating Officer since September 2006 and prior to that, as Executive Vice President and Chief Business Officer and Senior Vice President of Business Development. He has served on the Board of Directors since January 2008. Dr. Gorman is also a director of Xencor, Inc., a clinical-stage biopharmaceutical company. From 1990 until 1993, Dr. Gorman was a principal at Avalon Medical Partners, L.P., where he was responsible for the early-stage founding of the Company and several other biotechnology companies such as Onyx Pharmaceuticals, Inc., Metra Biosystems, Inc., Idun Pharmaceuticals, Inc. and ARIAD Pharmaceuticals, Inc. Dr. Gorman received his Ph.D. in Immunology and M.B.A. in Finance from the University of California, Los Angeles and did further post-doctoral training at The Rockefeller University.

What is Kevin Charles Gorman's net worth?

The estimated net worth of Kevin Charles Gorman is at least $58.61 million as of August 21st, 2023. Dr. Gorman owns 499,754 shares of Neurocrine Biosciences stock worth more than $58,611,149 as of December 9th. This net worth evaluation does not reflect any other assets that Dr. Gorman may own. Additionally, Dr. Gorman receives an annual salary of $1,900,000.00 as CEO at Neurocrine Biosciences. Learn More about Kevin Charles Gorman's net worth.

How old is Kevin Charles Gorman?

Dr. Gorman is currently 65 years old. There are 8 older executives and no younger executives at Neurocrine Biosciences. Learn More on Kevin Charles Gorman's age.

What is Kevin Charles Gorman's salary?

As the CEO of Neurocrine Biosciences, Inc., Dr. Gorman earns $1,900,000.00 per year. Learn More on Kevin Charles Gorman's salary.

How do I contact Kevin Charles Gorman?

The corporate mailing address for Dr. Gorman and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Kevin Charles Gorman's contact information.

Has Kevin Charles Gorman been buying or selling shares of Neurocrine Biosciences?

Kevin Charles Gorman has not been actively trading shares of Neurocrine Biosciences within the last three months. Most recently, Kevin Charles Gorman sold 9,328 shares of the business's stock in a transaction on Monday, August 21st. The shares were sold at an average price of $107.40, for a transaction totalling $1,001,827.20. Following the completion of the sale, the chief executive officer now directly owns 499,754 shares of the company's stock, valued at $53,673,579.60. Learn More on Kevin Charles Gorman's trading history.

Who are Neurocrine Biosciences' active insiders?

Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.

Are insiders buying or selling shares of Neurocrine Biosciences?

During the last year, Neurocrine Biosciences insiders bought shares 1 times. They purchased a total of 4,395,588 shares worth more than $39,032,821.44. During the last year, insiders at the sold shares 28 times. They sold a total of 176,946 shares worth more than $19,517,697.56. The most recent insider tranaction occured on December, 6th when insider Darin Lippoldt sold 20,830 shares worth more than $2,496,683.80. Insiders at Neurocrine Biosciences own 4.4% of the company. Learn More about insider trades at Neurocrine Biosciences.

Information on this page was last updated on 12/6/2023.

Kevin Charles Gorman Insider Trading History at Neurocrine Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/21/2023Sell9,328$107.40$1,001,827.20499,754View SEC Filing Icon  
2/8/2023Sell2,274$104.30$237,178.20491,365View SEC Filing Icon  
2/6/2023Sell3,040$105.68$321,267.20468,008View SEC Filing Icon  
1/31/2023Sell2,707$110.08$297,986.56465,278View SEC Filing Icon  
2/7/2022Sell8,710$80.82$703,942.20View SEC Filing Icon  
2/8/2021Sell10,466$116.75$1,221,905.50443,249View SEC Filing Icon  
2/5/2021Sell2,422$114.16$276,495.52443,249View SEC Filing Icon  
1/8/2021Sell308,250$110.22$33,975,315.00584,520View SEC Filing Icon  
11/12/2020Sell3,390$90.78$307,744.20441,071View SEC Filing Icon  
8/5/2020Sell3,390$118.91$403,104.90438,021View SEC Filing Icon  
4/24/2020Sell2,906$99.45$289,001.70434,971View SEC Filing Icon  
2/7/2020Sell3,248$103.35$335,680.80432,357View SEC Filing Icon  
2/5/2020Sell5,449$103.09$561,737.41423,351View SEC Filing Icon  
8/8/2019Sell80,000$95.31$7,624,800.00468,508View SEC Filing Icon  
8/6/2019Sell50,911$95.15$4,844,181.65468,508View SEC Filing Icon  
2/5/2019Sell7,614$88.16$671,250.24408,082View SEC Filing Icon  
5/1/2018Sell126,832$80.75$10,241,684.00473,865View SEC Filing Icon  
2/6/2018Sell105,983$80.25$8,505,135.75339,482View SEC Filing Icon  
1/16/2018Sell3,750$78.89$295,837.50View SEC Filing Icon  
5/2/2017Sell21,739$53.23$1,157,166.97354,346View SEC Filing Icon  
4/12/2017Sell19,596$50.42$988,030.32332,913View SEC Filing Icon  
2/6/2017Sell3,010$43.18$129,971.80250,542View SEC Filing Icon  
2/3/2017Sell3,125$42.55$132,968.75247,802View SEC Filing Icon  
1/17/2017Sell3,750$40.65$152,437.50244,677View SEC Filing Icon  
1/10/2017Sell3,750$43.28$162,300.00240,927View SEC Filing Icon  
2/3/2016Sell3,125$38.04$118,875.00228,077View SEC Filing Icon  
1/19/2016Sell3,750$46.70$175,125.00224,952View SEC Filing Icon  
1/11/2016Sell3,750$44.17$165,637.50221,202View SEC Filing Icon  
10/16/2015Sell33,500$47.77$1,600,295.00217,452View SEC Filing Icon  
3/24/2015Sell40,000$41.53$1,661,200.00View SEC Filing Icon  
1/16/2015Sell3,750$30.79$115,462.50View SEC Filing Icon  
1/12/2015Sell3,750$28.43$106,612.50View SEC Filing Icon  
1/8/2015Sell25,000$27.39$684,750.00View SEC Filing Icon  
12/19/2014Sell70,000$23.41$1,638,700.00View SEC Filing Icon  
1/10/2014Sell3,750$18.57$69,637.50180,952View SEC Filing Icon  
1/7/2014Sell108,000$16.76$1,810,080.00177,202View SEC Filing Icon  
See Full Table

Kevin Charles Gorman Buying and Selling Activity at Neurocrine Biosciences

This chart shows Kevin Charles Gorman's buying and selling at Neurocrine Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neurocrine Biosciences Company Overview

Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $117.28
Low: $117.23
High: $120.32

50 Day Range

MA: $112.36
Low: $106.07
High: $120.00

2 Week Range

Now: $117.28
Low: $89.04
High: $125.01


528,392 shs

Average Volume

732,433 shs

Market Capitalization

$11.52 billion

P/E Ratio


Dividend Yield